Alpha-1 antitrypsin deficiency (AATD) is an inherited condition characterized as a low or unpredictable level of alpha-1 protein, generated by liver. The disease most commonly affects lungs and liver and is often undiagnosed. Augmentation therapy is the most specific therapy for the treatment of AATD, and includes various preparations derived from pooled human plasma.
This report contains market size and forecasts of Alpha-1 Antitrypsin Deficiency Augmentation Therapy in Global, including the following market information:
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Alpha-1 Antitrypsin Deficiency Augmentation Therapy market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Glassia Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Alpha-1 Antitrypsin Deficiency Augmentation Therapy include Grifols, CSL, Baxter, Kamada, Takeda and Abeona, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Alpha-1 Antitrypsin Deficiency Augmentation Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, by Type, 2021 (%)
Glassia
Aralast NP
Prolastin C
Others
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, by Application, 2021 (%)
Hospitals
Specialty Clinics
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Alpha-1 Antitrypsin Deficiency Augmentation Therapy revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Grifols
CSL
Baxter
Kamada
Takeda
Abeona